



Attorney Docket No.: ALX-141

PATENT MAILED  
DEC 28 1995

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

GROUP 14-200

Applicant : Yi Wang, Louis Matis and Scott Rollins

Serial No.: 08/236,208

Filed: : May 2, 1994

For : METHOD FOR THE TREATMENT OF GLOMERULONEPHRITIS

Examiner : Phillip Gambel, Ph.D.

Group: : 1806

Commissioner of Patents and Trademarks  
Washington, D.C. 20231

MODIFIED 1449 FORM

---

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date below.

Date Mailed: December 12, 1995

12/12/95  
(Date Signed)

A handwritten signature in black ink, appearing to read "Seth A. Fidel".

Attorney Docket No.: ALX-141

*#7*  
T. Plunkett  
PATENT 2/14/98



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Yi Wang, Louis Matis and Scott Rollins

MAILED

DEC 28 1995

Serial No.: 08/236,208

GRANT ID 1814

Filed: May 2, 1994

For : METHOD FOR THE TREATMENT OF GLOMERULONEPHRITIS

Examiner : Phillip Gambel, Ph.D.

Group: 1806 1814

Commissioner of Patents and Trademarks  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date below.

Date Mailed: December 12, 1995

12/12/95

(Date Signed)

Seth A. Fidel, Ph.D.

INFORMATION DISCLOSURE STATEMENT


In accordance with 37 CFR §1.56 and 37 CFR §1.97(e)(1), applicants wish to call the Examiner's attention to Ann. Rev. Immunol. Volume 10, issued 1992, S.I. Morrison, "In Vitro Antibodies: Strategies for Production and Application," pages 239-265 listed on the Modified 1449 Form submitted herewith. A copy of this reference is enclosed.

The undersigned certifies that this reference was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement, i.e., in a September 13, 1995 Search Report regarding applicants' corresponding PCT patent application.

The Examiner is respectfully requested to initial a copy of the Modified 1449 Form and return it to applicants to indicate consideration of the reference listed thereon in connection with the prosecution of this application.

Respectfully submitted,

Date December 12, 1995

  
Seth A. Fidel, Ph.D.  
Reg. No. 38449  
Alexion Pharmaceuticals, Inc.  
25 Science Park  
New Haven, CT 06511